SRDX logo

Surmodics (SRDX) Company Overview

Profile

Full Name:

Surmodics, Inc.

Sector:

Healthcare

Country:

United States

IPO:

March 4, 1998

Indexes:

Not included

Description:

Surmodics, Inc. - a leading provider of medical devices and diagnostic technologies for healthcare system companies. The main focus is on cardiovascular diseases. The company was founded in 1979. The headquarters is located in the state of Minnesota. Surmodics, Inc. operates in two reporting business segments: the Medical Device Division - designs, develops, and manufactures interventional medical devices, primarily balloons and catheters for the treatment of peripheral artery diseases, urology, and others. The In Vitro Diagnostics Division - produces and sells components for diagnostic immunoassays, molecular tests, biomedical research.

Key Details

Price

$33.90

Annual Revenue

$126.08 M(-4.91% YoY)

Annual EPS

-$0.82(-645.45% YoY)

Beta

0.22

Events Calendar

Earnings

Next earnings date:

May 1, 2025

Recent quarterly earnings:

Jan 30, 2025

Recent annual earnings:

Nov 8, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 7, 2000

Analyst ratings

Recent major analysts updates

Jan 30, 25 Needham
Hold
Nov 7, 24 Needham
Hold
Aug 5, 24 Needham
Hold
May 30, 24 Barrington Research
Market Perform
May 29, 24 Sidoti & Co.
Neutral
May 29, 24 Needham
Hold
May 29, 24 Lake Street
Hold
May 2, 24 Barrington Research
Outperform
May 1, 24 Needham
Buy
Apr 10, 24 Needham
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
SRDX
zacks.comJanuary 31, 2025

Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SRDX
zacks.comJanuary 30, 2025

SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
SRDX
zacks.comJanuary 14, 2025

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
SRDX
zacks.comJanuary 3, 2025

SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
SRDX
zacks.comNovember 12, 2024

SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.

Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
SRDX
zacks.comNovember 7, 2024

SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SRDX
zacks.comNovember 6, 2024

SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.

SRDX Stock Down Despite FDA Clearance for Pounce XL System
SRDX Stock Down Despite FDA Clearance for Pounce XL System
SRDX Stock Down Despite FDA Clearance for Pounce XL System
SRDX
zacks.comOctober 2, 2024

Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.

Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
SRDX
zacks.comSeptember 5, 2024

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SRDX
zacks.comAugust 15, 2024

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

FAQ

  • What is the ticker symbol for Surmodics?
  • Does Surmodics pay dividends?
  • What sector is Surmodics in?
  • What industry is Surmodics in?
  • What country is Surmodics based in?
  • When did Surmodics go public?
  • Is Surmodics in the S&P 500?
  • Is Surmodics in the NASDAQ 100?
  • Is Surmodics in the Dow Jones?
  • When was Surmodics's last earnings report?
  • When does Surmodics report earnings?
  • Should I buy Surmodics stock now?

What is the ticker symbol for Surmodics?

The ticker symbol for Surmodics is NASDAQ:SRDX

Does Surmodics pay dividends?

No, Surmodics does not pay dividends

What sector is Surmodics in?

Surmodics is in the Healthcare sector

What industry is Surmodics in?

Surmodics is in the Medical Devices industry

What country is Surmodics based in?

Surmodics is headquartered in United States

When did Surmodics go public?

Surmodics's initial public offering (IPO) was on March 4, 1998

Is Surmodics in the S&P 500?

No, Surmodics is not included in the S&P 500 index

Is Surmodics in the NASDAQ 100?

No, Surmodics is not included in the NASDAQ 100 index

Is Surmodics in the Dow Jones?

No, Surmodics is not included in the Dow Jones index

When was Surmodics's last earnings report?

Surmodics's most recent earnings report was on Jan 30, 2025

When does Surmodics report earnings?

The next expected earnings date for Surmodics is May 1, 2025

Should I buy Surmodics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions